In early animal tests, the experimental TDN triggered weight loss without nausea or vomiting.
People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to discontinue use.
New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI cutoff—has become a "public health emergency."
New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone levels.
Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?
People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, researchers in Italy have found.
Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug on the market.
Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia.
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent mandate. Hims pushed back against the accusation.
Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.
Popular weight loss drugs promise to slim waistlines and improve our general health, but they also come with some unpleasant side effects involving our face, mouth, and teeth.
By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body mass while still trimming pounds.
Lars Fruergaard Jørgensen is out.
Not sure Musk is the poster boy Ozempic is looking for.
Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.
Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.
New research finds that ER visits related to semaglutide use might be on the rise.
Even the solid proposals set out by the Trump administration are being undermined by its actions taken elsewhere.
A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.
A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type 2 diabetes.
